Prescription stimulant consumption in the United States compared with 35 other countries
Open Access
- 29 May 2026
- journal article
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (6) , qxag133
Abstract
Introduction: Previous studies have identified the United States as a global outlier in stimulant prescribing. Given that stimulant prescribing in the United States has continued to increase, we aimed to provide current international comparisons. Methods: We analyzed 2024 stimulant consumption data from the International Narcotics Control Board, reported as defined daily doses for statistical purposes (S-DDD) per 1000 population per day. We compared the United States with 35 Organization for Economic Cooperation and Development members. Results: Overall, the United States comprised 26.8% of the population and consumed 67.6% of prescription stimulants. Per 1000 population per day, the United States had the second highest prescription stimulant consumption after Iceland. The volume of prescription stimulants consumed in the United States per 1000 population per day was 569% of the mean of comparison countries. Further, only 31.2% of consumed prescription stimulants in the United States was methylphenidate, vs 88.8% in comparison countries. Conclusion: Additional research is needed on the clinical and public health consequences of these major differences in controlled substance policy and clinical practice between the United States and other countries. For example, findings suggest a need to better understand any differential addictive potential of prescription stimulant regimens.Keywords
This publication has 12 references indexed in Scilit:
- Manufacturing Supply Chains and Imports in the ADHD Drug ShortageJAMA Health Forum, 2026
- Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 YearsJAMA Psychiatry, 2025
- ADHD Pharmacotherapy and Mortality in Individuals With ADHDJAMA, 2024
- Attention-deficit/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal studyeClinicalMedicine, 2023
- Opioid availability statistics from the International Narcotics Control Board do not reflect the medical use of opioids: comparison with sales data from ScandinaviaScandinavian Journal of Pain, 2021
- Disparate regulatory status of methylphenidate for adults with ADHD across EuropeThe Lancet Psychiatry, 2020
- Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016PLOS ONE, 2018
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysisThe Lancet Psychiatry, 2018
- The Global Market For ADHD MedicationsHealth Affairs, 2007
- International Health Care SpendingHealth Affairs, 1986